Dear editor,
The authors of the SIESTA trial 1 present a protocol with a laudable goal to ascertain the role of general anesthesia (GA) during endovascular stroke treatment (EST). Unfortunately, there are several issues with the trial.
The most important limitation of antecedent studies and the SIESTA protocol has been lack of anesthetic details and the lack of inputs from anesthesiologists. We point out that GA 6 ¼ intubation and intubation 6 ¼ GA. Stroke patients can receive GA and yet not require intubation, or require intubation but not be under GA. Moreover, using ETCO 2 is unreliable to determine respiratory failure and the need for GA. Therefore, the randomization categories are arbitrary and do not reflect the relevant neuropharmacology of GA nor physiologic indications for GA.
Additionally, GA constitutes a continuum of central nervous system depression, wherein effects on the brain are dose-related, disparate, and protean in terms of neurochemistry, perfusion, neuroprotection, and neurotoxicity. The term ''conscious sedation'' is an oxymoron. Anesthetic details really must be defined. The importance of this is illustrated in a recent report of EST outcomes varying with different anesthetics. 2 A related issue is lack of a plan for monitoring the depth of sedation. The proposed protocol mentions the use of Bispectral Index (BIS) but does not clarify whether anesthetic dose will be titrated to a targeted BIS value.
What is done with non-neurologic disorders? The same anesthetic approach is not appropriate in the context of many medical comorbidities and complicates randomization in an intention-to-treat paradigm.
These issues will produce another inconclusive study.
